

1 **Recombinant production of A1S\_0222 from *Acinetobacter baumannii* ATCC**  
2 **17978 and confirmation of its DNA-(adenine N6)-methyltransferase activity**

3 Ulrike Blaschke <sup>a</sup>, Beneditta Suwono <sup>a</sup>, Sachli Zafari <sup>b</sup>, Ingo Ebersberger <sup>b,c</sup>, Evelyn  
4 Skiebe <sup>a</sup>, Cy. M. Jeffries <sup>d</sup>, Dmitri I. Svergun <sup>d</sup> and Gottfried Wilharm <sup>a\*</sup>

5

6 <sup>a</sup> Robert Koch-Institute, Project group P2, Wernigerode, Germany

7 <sup>b</sup> Applied Bioinformatics Group, Institute of Cell Biology and Neuroscience, Goethe  
8 University, Frankfurt/Main, Germany

9 <sup>c</sup> Senckenberg Biodiversity and Climate Research Centre Frankfurt (BIK-F),  
10 Frankfurt/Main, Germany

11 <sup>d</sup> European Molecular Biology Laboratory (EMBL) Hamburg Outstation, 22607  
12 Hamburg, Germany

13 \* Corresponding address: Gottfried Wilharm, Robert Koch-Institut, Bereich  
14 Wernigerode, Burgstr. 37, D-38855 Wernigerode, Germany, e-mail:  
15 wilharmg@rki.de, Phone: +49 30 18754 4282; Fax: +49 30 18754 4207

16

17 **Abstract**

18 *Acinetobacter baumannii* appears as an often multidrug-resistant nosocomial  
19 pathogen in hospitals worldwide. Its remarkable persistence in the hospital  
20 environment is probably due to intrinsic and acquired resistance to disinfectants and  
21 antibiotics, tolerance to desiccation stress, capability to form biofilms, and is possibly  
22 facilitated by surface-associated motility. Our attempts to elucidate surface-  
23 associated motility in *A. baumannii* revealed a mutant inactivated in a putative DNA-  
24 (adenine N6)-methyltransferase, designated A1S\_0222 in strain ATCC 17978. We  
25 recombinantly produced A1S\_0222 as a glutathione S-transferase (GST) fusion  
26 protein and purified it to near homogeneity through a combination of GST affinity  
27 chromatography, cation exchange chromatography and PD-10 desalting column.  
28 Furthermore we demonstrate A1S\_0222-dependent adenine methylation at a  
29 GAATTC site. We propose the name AamA (*A*cinetobacter *a*denine

30 methyltransferase A) in addition to the formal names  
31 M.AbaBGORF222P/M.Aba17978ORF8565P. Small angle X-ray scattering (SAXS)  
32 revealed that the protein is monomeric and has an extended and likely two-domain  
33 shape in solution.

34

35 **Keywords:** *Acinetobacter baumannii*, DNA-adenine-methyltransferase, epigenetic,  
36 recombinant, *E.coli*, AamA, M.AbaBGORF222P

37

### 38 **Highlights**

- 39 • First purification of a m6A DNA methyltransferase from *Acinetobacter*  
40 *baumannii* (AamA)
- 41 • Verification of methyltransferase activity of AamA *in vitro*
- 42 • Monomeric structure of AamA confirmed by SAXS
- 43 • AamA is ubiquitously present in *Acinetobacter* spp.

### 44 **Abbreviations**

45 SAXS, small angle X-ray scattering; DESY, Deutsches Elektronen-Synchrotron; GST,  
46 glutathione S-transferase; m6A, methylation of the adenosine base at the nitrogen-6  
47 position

48

### 49 **Introduction**

50 *Acinetobacter baumannii* is a gram-negative opportunistic pathogen that causes  
51 nosocomial infections including pneumonia and bloodstream infections which is  
52 associated with an increased mortality and multi-drug resistance [1-3]. *A. baumannii*  
53 was rated as one of the critical priority 1 pathogens for the development of new  
54 antibiotics by the WHO in 2017 [4].

55 Despite the name “Acinetobacter” meaning non-motile bacteria and despite  
56 the lack of flagella, members of the genus are able to move [5, 6]. At least two forms  
57 of motility are known for *Acinetobacter* species. The so called “twitching motility”  
58 depends on retraction of type IV pili [7-9]. Another form of movement, the surface-

59 associated motility, occurs at the surface of semi-dry media and is independent of  
60 type IV pili [10]. Almost all tested clinical isolates can move along surfaces [11] and a  
61 number of genes required for this form of motility have been identified [10, 12, 13].

62 Motility is known to be affected by epigenetic regulation in various bacteria  
63 [14]. Epigenetics deals with heritable changes in gene expression without any  
64 changes in the DNA sequence. In bacteria the most studied epigenetic mechanism is  
65 DNA methylation [15] that is performed by DNA methyltransferases [16]. These  
66 enzymes transfer methyl groups from S-adenosyl-L-methionine (SAM) to adenine or  
67 cytosine bases. This process protects DNA against digestion from restriction  
68 endonucleases and is important for the regulation of various physiological processes  
69 such as mismatch repair and transcription [17, 18]. Most DNA methyltransferases are  
70 part of a restriction-modification system (R-M system). In this case the host DNA gets  
71 methylated by the DNA methyltransferase that protects the DNA against digestion by  
72 the corresponding endonuclease [19]. In addition, “orphan” methyltransferases are  
73 known that act without any associated endonuclease [17]. The most studied orphan  
74 DNA adenine methyltransferase called Dam was found in *E. coli* and was shown to  
75 methylate adenine bases at GATC sites [20, 21]. *Salmonella enterica dam* mutants  
76 exhibit a reduced motility [22] and *dam* overexpression in *Yersinia enterocolitica*  
77 resulted in an increased motility [23].

78 The *Acinetobacter baumannii* genome encodes a putative DNA-(adenine N6)-  
79 methyltransferase, designated A1S\_0222 in strain ATCC 17978 that seems to act  
80 without a corresponding endonuclease. We hypothesized that the putative DNA  
81 adenine methyltransferase A1S\_0222 does impose epigenetic control in  
82 *Acinetobacter baumannii* and since little is known about orphan methyltransferases  
83 we approached its characterization.

84

## 85 **Materials and Methods**

86 **Bacterial transformation and the generation of a *A. baumannii* ATCC 17978**  
87 **mutant.** Transformation was performed by electroporation [24]. The EZ-Tn5™  
88 <KAN-2> transposon mutants in *A. baumannii* ATCC 17978 were generated by using  
89 the EZ-Tn5™ <KAN-2> insertion kit (Epicentre Biotechnologies) as previously  
90 described [11].

91 **Surface-associated motility.** Motility plates were composed of 0.5% agarose (w/v),  
92 5 g/L of tryptone, and 2.5 g/L of NaCl as previously described [11]. A single colony  
93 from a nutrient agar plate (Oxoid) or selective agar plates (supplemented with 50  
94 µg/mL of kanamycin for the A1S\_0222 mutant) of either wild-type or *A. baumannii*  
95 ATCC 17978 mutant was taken with the pipette tip and then the surface of a motility  
96 plate was touched. Pictures were taken after incubating the plates for 16 h at 37°C.

97 **Construction of protein expression plasmids.** The *a1s\_0222* gene of *A.*  
98 *baumannii* ATCC 17978 was amplified by PCR using the oligonucleotides *0222-*  
99 *pGEX-6P-3-for*: 5'-ATTAGGATCCAATTCAGAGCCTTCGGTATACCAC-3' (BamHI  
100 restriction site underlined) and *0222-pGEX-6P-3-rev*: 5'-  
101 ATTAGCGGCCGCTTACCAAAGTGCGAGCTGTGTAC-3' (NotI restriction site  
102 underlined). The amplified *a1s\_0222* gene was inserted into pGEX-6P-3 expression  
103 vector (GE Healthcare) after digestion of insert and vector with BamHI and NotI  
104 restriction enzymes. The pGEX-6P-3 expression vector carries a glutathione S-  
105 transferase (GST-tag) gene, a PreScission protease restriction site, an ampicillin  
106 resistance (Amp<sup>R</sup>) cassette, encodes a *tac* promoter and is inducible with isopropyl  
107 β-D-1-thiogalactopyranoside (IPTG). The plasmid (pGEX-6P-3-A1S\_0222) was  
108 confirmed by DNA sequencing and transformed into *E. coli* BL21 (DE3) pLysS  
109 expression strain.

110 **Protein expression and purification.** A 3 mL overnight culture of *E. coli* BL21 (DE3)  
111 pLysS pGEX-6P-3-A1S\_0222 was grown in Luria-Bertani (LB)-Medium (10 g/L  
112 tryptone, 5 g/L yeast extract, 5 g/L NaCl, pH 7.4, 100 µg/mL Amp) at 37°C and 160  
113 rpm. The overnight culture was diluted 1:100 into 200 mL LB (supplemented with 100  
114 µg/mL Amp) and cultured in a 2 L bottle-flask at 20°C and 160 rpm for 5 hours.  
115 Expression was induced by addition of 0.05 mM IPTG and cultures were incubated  
116 for 16 h at 20°C and 160 rpm. Cells were then harvested by centrifugation (10,000 ×  
117 *g* for 30 min at 4°C) and the resulting cell pellets were frozen at -80°C. Cell pellets  
118 were solubilized at 4°C in 20 mL disruption buffer (300 mM NaCl, 1 mM DTT (1,4-  
119 dithiothreitol), 5 mM EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-  
120 tetraacetic acid), 1 mM EDTA (2,2',2'',2'''-(ethane-1,2-diyldinitrilo) tetraacetic acid), 2  
121 µL benzonase nuclease (250 U/µL), pH 7.4. The cells were lysed by applying three  
122 passages through an EmulsiFlex-C3 homogenizer (Avestin). Lysates were then

123 centrifuged at 20,000 × *g* for 50 min at 4°C. The soluble lysate was then added to a  
124 GSTPrep™ FF 16/10 column (GE Healthcare Life Sciences).

125 **GST affinity chromatography.** The GSTPrep™ FF 16/10 column (bed volume 20  
126 mL) was equilibrated with 5 column volumes (CV) of GST binding buffer (300 mM  
127 NaCl, 1 mM DTT, 5 mM EGTA, 1 mM EDTA, 5% glycerol (v/v), pH 7.4). The soluble  
128 lysate was added to the column and washed with 10 CV of GST binding buffer and  
129 eluted with 7 CV of GST elution buffer (300 mM NaCl, 50 mM Tris, 1 mM DTT, 5 mM  
130 EGTA, 1 mM EDTA, 5% glycerol (v/v), 10 mM reduced L-glutathione (GSH reduced),  
131 pH 7.4). Eluted fractions were analyzed by SDS-PAGE and appropriate fractions  
132 were pooled. The GST fusion protein was then incubated for 16 h at 8°C with 40  
133 units PreScission protease per 14.52 mg recombinant A1S\_0222 to cleave off the  
134 GST tag (26 kDa). After incubation the pooled fractions were centrifuged at 20,000 *g*  
135 for 20 min at 4°C and diluted 1:4 in dilution buffer (50 mM Tris, 1 mM EDTA, 1 mM  
136 DTT, 5% glycerol (v/v)).

137 **Cation exchange chromatography (CEC).** The HiTrap™ SP XL (GE Healthcare  
138 Life Sciences) column (bed volume 1 mL) was equilibrated with 10 column volumes  
139 (CV) CEC binding buffer (50 mM NaCl, 50 mM Tris, 1 mM DTT, 1 mM EDTA, 5%  
140 glycerol (v/v)). The protein solution was loaded on the column and the column  
141 washed with 5 CV CEC binding buffer and subsequently eluted with 30 CV in a linear  
142 gradient from 0% to 100% of CEC elution buffer (1000 mM NaCl, 50 mM Tris, 1 mM  
143 DTT, 1 mM EDTA, 5% glycerol (v/v)). Eluted fractions were analyzed by reducing  
144 sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), pooled and  
145 loaded on a PD-10 desalting column.

146 **PD-10 desalting column.** The PD-10 desalting (GE Healthcare Life Sciences)  
147 column was equilibrated with buffer B1. Further steps were performed as described  
148 in the column manual using a gravity desalting protocol. The A1S\_0222 protein was  
149 eluted with buffer B1 (150 mM NaCl, 10 mM Tris, 1 mM DTT and 5% glycerol (v/v),  
150 pH 7.4). Pooled fractions were concentrated using the Vivaspin® concentrator with a  
151 molecular weight cutoff of 10,000 Dalton and a Hydrosart (HY) membrane (Sartorius  
152 Stedim Biotech). The purity of A1S\_0222 was analyzed by reducing SDS-PAGE.  
153 Protein concentrations were determined using the Bradford method. Purified  
154 A1S\_0222 was directly used for further analysis or stored at -80°C.

155 **Confirmation of the A1S\_0222 DNA methylation recognition site.** To confirm the  
156 A1S\_0222 DNA methylation recognition site, the 800 base-pair (bp) PCR product,  
157 Int1, consisting of the 5'-end of the *a1s\_0222* gene from *A. baumannii* ATCC 17978,  
158 was incubated with and without purified A1S\_0222 at 37°C for one hour (3 µL Int1  
159 (about 200 ng/µL), 2 µL B1 buffer, 4 µL of 800 µM S-adenosyl-L-methionine (SAM), 3  
160 µL A1S\_0222 (2.46 µg/µL), 8 µL RNase free water). Int1 was amplified with the  
161 oligonucleotides *Int1-for*: 5'-GGATCCGGATGAAATGATCAGTTATGTGGC-3' and  
162 *Int1-rev*: 5'-CGCTCTAATGCTGTTTGTGTACG-3'. Samples of methylated and non-  
163 methylated Int1 DNA were used for Sanger DNA sequencing and analyzed at the  
164 Robert Koch-Institute sequencing lab (Berlin, Germany) on an ABI PRISM analyzer.  
165 The sequencing chromatograms were analyzed as described previously [25].

166 **DNA methylation assay.** To test the biological activity of purified A1S\_0222, a  
167 methylation assay was performed using the Int1 DNA. As an alternative DNA  
168 substrate, Seq3 (located in gene A1S\_0965 of *A. baumannii* ATCC 17978) was  
169 amplified from *Acinetobacter baumannii* 29D2 using the oligonucleotides *Seq3-for*:  
170 5'-GAAGTCACTGATACCAAGGAAGGTATTCATTTTG-3' and *Seq3-rev*: 5'-  
171 GTCTGGAAAATGCTGTGTTTCTAATGCTAG-3' (801 bp). Each fragment contains  
172 one *EcoRI* restriction site (G↓AATTC). For the methylation reaction 1 µg of Int1 or  
173 Seq3, 2 µL B1 buffer, 4 µL of 800 µM SAM, 8 µL RNase free water and 3 µL  
174 A1S\_0222 (2.46 µg/µL) or 40 units *EcoRI* methyltransferase (New England BioLabs)  
175 were mixed and incubated for up to one hour at 37°C. After incubation A1S\_0222 or  
176 *EcoRI* methyltransferase was inactivated by 95°C for 5 minutes and Int1 or Seq3  
177 were purified with Hi Yield® Gel/PCR DNA Fragment Extraction Kit (SLG®) according  
178 to the manufacturer's instructions and eluted in 10 µL RNase free water.  
179 Subsequently, an *EcoRI* restriction reaction was performed (5 µL purified Int1 or  
180 Seq3, 1 µL *EcoRI*, 2 µL *EcoRI* buffer, 12 µL RNase free water) for 2 hours at 37°C.  
181 For visualization, agarose electrophoresis was carried out at 110 V for 50 min in TAE  
182 buffer (agarose concentration: 1.25% (w/v)). GelRed™ (GeneON) was used for gel  
183 staining. GelRed™ stock solution was diluted 1:5000 into the agarose gel solution.  
184 As a size standard GeneRuler DNA Ladder Mix (Thermo Fisher Scientific) was used.  
185 The methyltransferase activity was calculated based on the definition that 1 unit (U)  
186 of enzyme converts 1 µmol of substrate per minute at 37°C.

187 **Small angle X-ray scattering (SAXS).** Synchrotron SAXS measurements ( $I(s)$  vs  $s$ ,  
188 where  $s = 4\pi\sin\theta/\lambda$ ;  $2\theta$  is the scattering angle and  $\lambda=0.125$  nm) were performed at  
189 the EMBL-P12 bioSAXS beam line at the PETRA III storage ring (DESY, Hamburg)  
190 as described in [26] under continuous-flow batch mode operations at 10°C utilizing an  
191 automated robotic sample changer [27]. The scattering intensity data were recorded  
192 from 25  $\mu$ l aliquots of A1S\_0222 (2.4 mg/mL) and a corresponding matched solvent  
193 blank (150 mM NaCl, 10 mM Tris, 1 mM DTT and 5% glycerol, pH 7.4) as a series of  
194 sequential 50 ms 2D-data frames for a total exposure time of 1 s (Pilatus 2M photon  
195 counting detector). The resulting individual 50 ms 2D-frames underwent radial  
196 averaging to produce unsubtracted 1D  $I(s)$  vs  $s$  scattering profiles [28]. Additional  
197 statistical checks were employed through the data reduction process so as not to  
198 include any sample (or buffer) frames affected by radiation damage (or systematic  
199 scaling errors) in the final, reduced 1D scattering profiles [29]. The scattering from  
200 the buffer was subtracted from the sample scattering to generate the final SAXS  
201 profile measured across an  $s$ -range of 0.013-3.8 nm<sup>-1</sup>. From these data, several  
202 structural parameters were extracted using the ATSAS 2.8 software package [30].  
203 First, the number of Shannon channels and maximum working  $s$  was assessed using  
204 *SHANUM* (Shannon channels = 14;  $s_{\max} = 3.2$  nm<sup>-1</sup>: [31]). The extrapolated forward  
205 scattering intensity at zero angle,  $I(0)$  and the radius of gyration  $R_g$ , were determined  
206 from both the Guinier approximation ( $\ln I(s)$  vs  $s^2$ , in the  $s$ -range of  $0.22 < sR_g < 1.3$ ,  
207 defining a working  $s_{\min}$  of 0.07 nm<sup>-1</sup>; [32]) and from the probable real-space distance  
208 distribution ( $\rho(r)$  vs  $r$  profile) calculated from the indirect inverse Fourier transform of  
209 the data using *GNOM* [33]. The latter was also used to evaluate the maximum  
210 particle dimension,  $D_{\max}$ . The molecular weight (MW) estimate of A1S\_0222 was  
211 assessed using both concentration-dependent and concentration-independent  
212 methods. The concentration-independent MW methods included that of [34], the  
213 ‘volume’ of correlation,  $V_c$ , from [35] and the empirical correction to the Porod  
214 volume,  $V_p$ , as described in [36] as implemented in the respective ATSAS dattools  
215 *DATMOW*, *DATVC* and *DATPOROD*. The concentration-dependent MW estimate  
216 was performed relative to a bovine serum albumin (BSA) standard using the  
217 extrapolated  $I(0)$  and the sample concentration (described in [37]). The final spatial  
218 representation of A1S\_0222 – classified as compact using *DATCLASS* with an  
219 *AMBIMETER* shape ambiguity score of 0.9, i.e., as potentially unique [38] was  
220 obtained using *ab initio* bead modeling implemented in the program *DAMMIN* [39].

221 Ten individual bead models were generated that fit the data (assessed using the  
222 reduced  $\chi^2$  test and the Correlation Map, or CorMap, p-value. A  $\chi^2$  of 1 and  $p > 0.01$   
223 indicate no systematic discrepancies between the data-model fit [29]). The individual  
224 models were spatially aligned using *SUPCOMB* where the normalized spatial  
225 discrepancy (NSD) of the 10 model ensemble was assessed at 0.5 (aligned models  
226 with  $NSD < 1$  are considered similar [40]). The models were subsequently averaged  
227 and bead occupancy-corrected using *DAMAVER* [41] and refined against the SAXS  
228 data using *DAMMIN/DAMSTART* to produce a final average 3D-spatial  
229 representation of A1S\_0222 at an estimated resolution of 2.5 nm [42]. The SAXS  
230 data,  $p(r)$  vs  $r$  profile, as well as the individual, averaged and refined DAMMIN  
231 models and the associated fits are deposited in the Small-angle Scattering Biological  
232 Data Bank with the accession code SASDD32 (SASBDB: [www.sasbdb.org](http://www.sasbdb.org), [43]).

233 **Structural homology modelling.** Intensive Phyre2 modelling [44] was performed  
234 using the primary amino acid sequence of A1S\_0222 as input to generate an  
235 atomistic 3D-homology model of A1S\_0222. The fit to the SAXS data of the  
236 homology model as well as the fit to the data of the *E. coli* adenine-N6-DNA-  
237 methyltransferase, TaqI (Protein databank, PDB, accession 2ADM, chain A) were  
238 assessed using *CRY SOL* with 25 harmonics and a constant employed [45].  
239 Additional normal mode structural refinement of the A1S\_0222 homology model was  
240 performed using *SREFLEX* [46].


241 **Phylogenetic profiling.** We determined the presence absence pattern of orthologs  
242 to A1S\_0222 across 1,548 *A. baumannii* strains, and 437 other taxa in the genus  
243 *Acinetobacter*. The ortholog search was performed in two stages. In stage one, we  
244 used the OMA algorithm [47] to compile an initial set of orthologous sequences from  
245 an all-against-all ortholog search in 104 representative *Acinetobacter* spp.  
246 representing all type strains. We then used this core orthologous group for a targeted  
247 ortholog search in the remaining taxa with HaMStR [48].

248

## 249 **Results and Discussion**

250 **Motility assays.** Preparing a library of *A. baumannii* ATCC 17978 mutants deficient  
251 in surface-associated motility, we found a knock out mutant of a putative DNA-  
252 (adenine N6)-methyltransferase, designated A1S\_0222 in strain ATCC 17978. Figure


253 1 represents the motility deficiency of the A1S\_0222 mutant in strain ATCC 17978.  
254 This A1S\_0222-specific motility deficiency could be confirmed in other *A. baumannii*  
255 strains, for instance DSM 30011 (data not shown) and 29D2 (data not shown; [49]).



256

257 **Fig. 1: The A1S\_0222 mutant is deficient in surface-associated motility.** *A.*  
258 *baumannii* ATCC 17978 (WT) and ATCC 17978 *a1s\_0222::Km* (mutant) were  
259 inoculated on motility plates twice each and incubated for 16 h at 37°C. One  
260 representative picture is shown.

261 **A1S\_0222 protein overexpression and purification.** To recombinantly produce the  
262 A1S\_0222 protein, the *a1s\_0222* gene was amplified by PCR and cloned into the  
263 expression vector pGEX-6P-3 designed for expression of glutathione S-transferase  
264 (GST)-fusion proteins. The plasmid insert was confirmed by DNA sequencing and  
265 transformed into *E. coli* BL21 (DE3) pLysS for expression. Preliminary experiments  
266 revealed that the best conditions for protein expression are the induction with 0.05  
267 mM IPTG and the incubation at 20°C for 16 hours (data not shown). The GST-  
268 A1S\_0222 fusion protein was purified from a 200 mL *E. coli* culture and the soluble  
269 lysate was loaded on a GSTPrep™ FF 16/10 column. Eluted fractions were pooled  
270 and GST tag was cleaved off by PreScission protease. The protein was further  
271 purified using HiTrap™ SP XL column (cation exchange chromatography, CEC) and  
272 subsequently high-salt buffer (430 mM NaCl) was changed into a low-salt buffer (150  
273 mM NaCl) using a PD-10 column. The molecular weight of A1S\_0222 is about 48  
274 kDa. The protein then was concentrated to about 2.5 mg/mL with the best  
275 concentration results being achieved with a Hydrosart membrane (10,000 Da  
276 MWCO) although concentration of the protein remained inefficient. The purification of  
277 A1S\_0222 is illustrated in Figure 2 and summarized in Table 1. We were able to  
278 purify A1S\_0222 to near homogeneity.



279

280 **Fig. 2: Protein expression and purification of A1S\_0222.** Coomassie-stained  
 281 SDS-PAGE showing the soluble fraction of the cell lysate after centrifugation  
 282 (“soluble”), the fractions of GST-A1S\_0222 after GST affinity chromatography  
 283 (“GST”), cleavage of the GST-tag (26 kDa) after treatment with PreScission protease  
 284 (“protease”), purified A1S\_0222 (48 kDa) after cation exchange chromatography  
 285 (“CEC”) and after subsequent desalting using a PD-10 column (“PD-10”).

286

287 **Table 1:** Purification of A1S\_0222 recombinantly produced from a 200 mL *E. coli*  
 288 culture

Purification step	Total volume [mL]	Protein conc. [mg/mL]	Total protein [mg]	Total A1S_0222 [mg]	Purity A1S_0222* [%]	Purification [fold]	Specific activity [mU/mg]
Soluble bacterial lysate	15	8.07	121.18	19.99	14.8	1	-
GSTPrep™	8	2.46	19.68	16,03	81.5	5.5	-
HiTrap™	4	2.41	9.64	9.29	96.4	6.5	-
PD-10	5	1.73	8.65	8.33	96.4 <sup>a</sup>	6.5	-
Vivaspin® HY	1.5	2.46	3.69	3.55	96.4 <sup>b</sup>	6.5	0.013

289 \* Purity of A1S\_0222 was determined by using ImageJ software and refers to GST-A1S\_0222 (soluble  
 290 bacterial lysate and GSTPrep™) and A1S\_0222 without GST (HiTrap™; PD-10 and Vivaspin® HY),  
 291 respectively.


292 <sup>a</sup> Due to background variation in the Coomassie-stained gel, the determined purity (with ImageJ) was  
 293 adjusted to the purity of A1S\_0222 after cation exchange chromatography (HiTrap™).

294 <sup>b</sup> A1S\_0222 purity was comparable before and after concentration on Vivaspin® HY concentrators.

295

296 **Identification of the A1S\_0222 DNA recognition sequence and**  
297 **methyltransferase activity.** According to REBASE, a database in which information  
298 about restriction enzymes, DNA methyltransferases, recognition and cleavage sites,  
299 published and unpublished references are collected [50, 51], the *A. baumannii*  
300 methyltransferase A1S\_0222 was found to be annotated as M.AbaBGORF222P and  
301 M.Aba17978ORF8565P recognizing the RAATTY DNA sequence. DNA adenine  
302 methyltransferases, sharing the same recognition site as A1S\_0222 were found in  
303 various bacteria including the MTase M.Hpy300III (GAATTC) from *Helicobacter pylori*  
304 isolate BCM-300 and M.Mpa1757II (GAATTC) from *Microcystis panniformis* FACHB-  
305 1757 (<http://rebase.neb.com/rebase/rebase.html>). Unfortunately most m6A  
306 methyltransferases in this database are not yet biochemically characterized. To  
307 detect the recognition site of A1S\_0222, Sanger DNA sequencing was performed  
308 (Figure S1). In this automated dye terminator sequencing, m6A methylations in  
309 template DNA are identified by an increased complementary T signal [25]. As a  
310 consequence the recognition site of A1S\_0222 was detected to be GAATTC in which  
311 the second adenine (underlined) gets methylated. This recognition sequence equates  
312 to the restriction site of the endonuclease EcoRI (GAAATTC). As the next step we  
313 confirmed the enzymatic activity of the purified m6A methyltransferase A1S\_0222.  
314 Therefore a methylation/restriction protection assay was established (Figure 3). A  
315 template-DNA (Int1), which contains only one A1S\_0222 recognition site/EcoRI  
316 restriction site, was amplified by PCR. The purified PCR product Int1 was treated  
317 with A1S\_0222 and afterwards incubated with and without EcoRI. As a control, Int1  
318 was not treated with A1S\_0222 but also incubated in the presence and absence of  
319 EcoRI. After incubation of Int1 with A1S\_0222, EcoRI is no longer able to restrict the  
320 DNA Int1 (Figure 3, lane “+/+”), whereas Int1 gets restricted into 2 fragments without  
321 the A1S\_0222 treatment (Figure 3, lane “-/+”). Thus, the results demonstrate the  
322 biological activity of the purified A1S\_0222 as a DNA-(adenine N6)-  
323 methyltransferase. Note, that we did not observe any DNA degradation in this assay,  
324 demonstrating a DNase-free purification of A1S\_0222. To address the specific  
325 activity of A1S\_0222, a kinetic analysis of the methylation reaction was performed as  
326 described before. To this end, the methylation reaction was stopped and analyzed by

327 agarose gel electrophoresis after 10 min, 20 min, 30 min and 40 min (Figure 4).  
328 When incubating A1S\_0222 for 10 min with 1  $\mu$ g of DNA (Int1) half of the DNA was  
329 methylated and therefore protected from EcoRI restriction (lane “+/+”, Figure 4). After  
330 40 min 1  $\mu$ g of DNA was completely methylated by A1S\_0222 and could not be  
331 digested by EcoRI anymore. The specific activity of A1S\_0222 was calculated to be  
332 approximately 0.013 mU/mg (Table 1). This low specific activity was confirmed using  
333 different DNA fragments (amplified from the *A. baumannii* 29D2 chromosome). One  
334 representative example is shown in Figure S2. In this case, about 80% of DNA is  
335 methylated by A1S\_0222 after 40 minutes of incubation. The specific activity of 0.013  
336 mU/mg for A1S\_0222 is low compared to other orphan methyltransferases. For  
337 example, the most prominent *E. coli* DNA adenine methyltransferase, Dam, shows a  
338 specific activity of about  $8.9 \times 10^5$  U/mg [52]. As general proof of the suitability of the  
339 assay conditions, all tested DNA fragments were also treated with a commercial  
340 EcoRI methyltransferase from *E. coli* RY13 (New England BioLabs). Figures 4(B)  
341 and S2(B) illustrate that EcoRI methyltransferase confers full protection from EcoRI  
342 restriction within 30 seconds of incubation.




343

344 **Fig. 3: Purified A1S\_0222 protects DNA from EcoRI restriction.** PCR-amplified  
345 DNA Int1 (800 bp) harboring a single EcoRI restriction site (GJAATTC) was used for  
346 testing the biological activity of the putative DNA-(adenine N6)-methyltransferase  
347 A1S\_0222. Methylation reaction was performed for 1 h at 37°C in the presence of  
348 160  $\mu$ M S-adenosyl-L-methionine (SAM). Subsequently, A1S\_0222 was inactivated  
349 at 95°C (5 min), DNA was purified and subjected to EcoRI restriction for 2 h at 37°C.  
350 In lane “-/-“ Int1 DNA was neither treated with A1S\_0222 nor with EcoRI. Lane “-/+”

351 indicates the absence of A1S\_0222 but the treatment of Int1 with EcoRI which results  
 352 in cleavage of Int1 into two fragments (629 bp and 171 bp). Incubation of Int1 with  
 353 A1S\_0222 but no subsequent treatment with EcoRI is indicated by “+/-“. Lane “+/+”  
 354 indicates incubation of Int1 with A1S\_0222 and subsequent treatment with EcoRI  
 355 suggesting that methylation of Int1 by A1S\_0222 protects the DNA against EcoRI  
 356 digestion.

357




358

359 **Fig. 4: Kinetic analysis of the A1S\_0222 methylation reaction (A) and**  
 360 **comparison to activity of EcoRI methyltransferase from *E. coli* RY13 (B).** 1  $\mu$ g of  
 361 DNA (Int1) was used for methylation assay as described in legend to Fig. 3.  
 362 Untreated Int1 is indicated by “-/-“. DNA (Int1) not treated with A1S\_0222 (7.38  $\mu$ g) or  
 363 EcoRI methyltransferase (40 U) but treated with EcoRI endonuclease is shown by “-/  
 364 +/“. Int1 incubated with A1S\_0222 or EcoRI methyltransferase but without *EcoRI*  
 365 endonuclease treatment is indicated by “+/-“. Int1 treated with A1S\_0222 and  
 366 subsequently treated with EcoRI endonuclease is shown by “+/+“. **A.** After 10  
 367 minutes of treatment with A1S\_0222, 0.5  $\mu$ g of DNA (50%) is protected from  
 368 restriction and after 40 minutes of incubation 1  $\mu$ g DNA is almost completely  
 369 methylated by A1S\_0222. **B.** After 30 seconds of treatment of the Int1 DNA with  
 370 EcoRI methyltransferase, all DNA (1  $\mu$ g) is methylated and consequently protected  
 371 from restriction by EcoRI endonuclease.

372 **Structural characterization of A1S\_0222.** Given the low specific activity of our  
 373 protein preparations and the considerable problems to concentrate the protein to  
 374 levels above 2.5 mg/mL, we employed SAXS to structurally characterize and

375 generate a low-resolution model of A1S\_0222 in solution. Figure 5 and Table 2  
376 summarize the SAXS results which demonstrate that the protein is monomeric. Both  
377 concentration-dependent MW (52 kDa) and concentration-independent MW  
378 estimates (45-60 kDa) are in the range of the expected MW calculated from the  
379 amino acid sequence for the monomer (49 kDa). The shape classification of the data  
380 and the resulting  $\rho(r)$  vs  $r$  profile indicate that A1S\_0222 forms a compact, slightly  
381 anisotropic structure with an  $R_g$  of  $\sim 3$  nm, with a  $D_{max}$  of  $\sim 11$  nm (Table 2). The  
382 consensus low-resolution (2.5 nm) DAMMIN bead model ( $\chi^2 = 1.06$ ; CorMap p =  
383 0.13) shows that A1S\_0222 is flattened in one dimension, with possible structural  
384 extensions from the predominantly compact core (refer to SASBDB entry SASDD32).  
385 Of interest, a simple search of the PDB for DNA methyltransferases and the  
386 subsequent fitting the atomic structure of the *E.coli* adenine-N6-DNA-  
387 methyltransferase, TaqI (PDB 2ADM chain A; [53]) to the SAXS data suggests that  
388 TaqI and A1S\_0222 may share structural features in common (Figure 6). Although  
389 the TaqI structure does not fit the SAXS data ( $\chi^2 = 2.5$ , CorMap p = 0), the modelled  
390 intensities of the TaqI methyltransferase are not totally dissimilar across the  
391 experimental A1S\_0222 SAXS profile which is surprising considering the two  
392 proteins only share 17 % amino acid sequence identity. Indeed subsequent Phyre2  
393 homology modelling of A1S\_0222, using the amino acid sequence of the protein as a  
394 template, consistently identified a number (more than 20) of high-scoring  
395 homologous fragments in the PDB (with greater than 97% confidence) that are  
396 categorized as DNA methyltransferases. The top-scoring homologues identified  
397 during the Phyre2 modelling are that of *E. coli* DNA adenine methyltransferase, PDB  
398 2G1P (chain B) and bacteriophage T4 DNA adenine methyltransferase, PDB 1YF3  
399 (chain A). As with TaqI, the final A1S\_0222 Phyre2 homology model shows  
400 significant statistical discrepancies when fitting the model to the SAXS data ( $\chi^2 = 2.6$ ;  
401 CorMap p = 0). However, if the Phyre2 A1S\_0222 homology model undergoes  
402 additional normal mode rigid-body refinement – that allows for subtle shifts in domain  
403 orientation – the predicted structure effectively ‘opens up’ and undergoes an overall  
404 extension to subsequently fit the SAXS data ( $\chi^2 = 1.2$ ; CorMap p = 0.019, Figure 6).



405

406 **Fig. 5: SAXS data and modelling.** **A.** SAXS data measured from A1S\_0222 used to  
 407 calculate  $p(r)$  vs  $r$  and for subsequent *ab initio* modelling (encompassing 10 out of 14  
 408 total Shannon channels;  $s_{\min}$ ,  $0.07 \text{ nm}^{-1}$ ;  $s_{\max}$ ,  $2.5 \text{ nm}$ ). **B.** The corresponding Guinier  
 409 plot and linear fit (white line;  $R^2 = 0.99$ ) determined in the range  $0.22 < sR_g < 1.3$ . **C.**  
 410 The corresponding probable real space distance distribution,  $p(r)$  vs  $r$ , calculated  
 411 from the inverse indirect Fourier transform of the data (reciprocal space fit to the  
 412 SAXS data:  $\chi^2 = 1.08$ , CorMap  $p = 0.16$ ). **D.** An individually refined low-resolution  
 413 (2.5 nm) DAMMIN bead model of A1S\_0222 derived from refining the averaged  
 414 superposition of 10 individual structures showing the shape and overall dimensions  
 415 of the protein in solution. The fit of the model to the SAXS data is shown in panel A  
 416 ( $\chi^2 = 1.06$ , CorMap  $p = 0.13$ ). Additional details can be located in the SASBDB entry  
 417 SASDD32 ([www.sasbdb.org](http://www.sasbdb.org)).

418

419


420

421 **Table 2:** A1S\_0222 SAXS structural parameters and modelling summary

<b>Guinier Analysis</b>		
$I(0)$ (error)	3766 a.u.	(+/- 7)
$R_g$ (error)	2.9 nm	(+/- 0.3 nm)
$qR_g$ range	0.22 < $sR_g$ < 1.3	
<b><math>\rho(r)</math> analysis</b>		
$I(0)$ (error)	3773 a.u.	(+/- 8)
$R_g$ (error)	3 nm	(+/- 0.01)
$D_{max}$	11 nm	
$q$ range	0.07—2.5 nm <sup>-1</sup>	
Reciprocal space fit: $\chi^2$ , CorMap p-value	$\chi^2 = 1.08$	p = 0.16
Porod volume, $V_p$	96 nm <sup>3</sup>	
MW from $I(0)$ and concentration (ratio to expected value, 49 kDa)	53 kDa	(1.08)
<i>Concentration independent MW estimates</i>		
From $V_p$ (Petoukhov et al 2012)	60 kDa	
From Fischer et al (2010)	48 kDa	
From $V_c$ (Rambo and Tainer, 2013)	45 kDa	
Shape Classification ( <i>DATCLASS</i> )*	compact	
<b><i>Ab initio</i> modelling</b>		
Symmetry	P1	
Ambiguity measure(s) ( <i>AMBIMETER</i> )	0.9	Potentially unique
Model fit $\chi^2$ , CorMap p-value	$\chi^2 = 1.06$	p = 0.13
Model volume and MW from DAM model	120 nm <sup>3</sup>	60 kDa
Model resolution*	2.5 nm	

422 \* *DATCLASS* is part of the ATSAS 2.8 suite of analytical dattools. \*\* The model resolution was  
 423 obtained via the spatial alignment of ten individual *ab initio* models as per the method of Tuukkanen *et*  
 424 *al.* 2016 [42].

425



426

427 **Fig. 6: Adenine-N6-DNA-methyltransferase models.** **A.** The structural  
 428 representation of the *E. coli* adenine-N6-DNA-methyltransferase, TaqI (PDB: 2ADM,  
 429 chain A; red ribbon) and the reported  $\chi^2$  discrepancy of the model-fit to the A1S\_0222  
 430 SAXS data. **B.** The predicted Phyre2 homology model of A1S\_0222 (blue ribbon)  
 431 constructed from homologous DNA methyltransferase structural templates. Although  
 432 the enzyme is predicted to have two major domains, in the relative spatial  
 433 orientations depicted here, the fit to the SAXS data remains poor. **C.** A significant  
 434 improvement in the fit to the SAXS data for the Phyre2 homology model occurs if the  
 435 predicted domains of A1S\_0222 shift orientation with respect to each other, i.e.,  
 436 rotate/move apart (grey arrows) to form a more extended structure (cyan surface).  
 437 **D.** The corresponding fits to the SAXS data of the modelled scattering intensities of  
 438 TaqI (red), the Phyre2 homology model (blue) and the Phyre2 A1S\_0222 structure  
 439 that has undergone a shift in the domain orientations (cyan).

440

441 **The phylogenetic relationship of A1S\_0222 to other *Acinetobacter* orphan DNA**  
 442 **methyltransferases.** Lastly, we analyzed the phylogenetic distribution of A1S\_0222  
 443 within *Acinetobacter* spp. Our analysis revealed that this protein is encoded in all but  
 444 19 of the 1,985 genomes covering the full known diversity of the genus  
 445 *Acinetobacter*. The 19 cases where no ortholog could be identified are shown in  
 446 Table 3. We see no obvious grouping of individual species where this gene is  
 447 missing. Instead, we conclude that this protein is ubiquitously present in  
 448 *Acinetobacter* spp.. Most probably, issues connected to data quality and the draft  
 449 status of most *Acinetobacter* spp. genome reconstructions explain the few cases  
 450 where no ortholog could be detected.

451

452 **Table 3:** *Acinetobacter* spp. lacking an ortholog to A1S\_0222

Assembly name	NCBI ID	Taxon name
GCF_000805035.1	470	<i>Acinetobacter baumannii</i>
GCF_000939415.2	470	<i>Acinetobacter baumannii</i>
GCF_001415065.1	470	<i>Acinetobacter baumannii</i>
GCF_001416235.1	470	<i>Acinetobacter baumannii</i>
GCA_001510805.1	471	<i>Acinetobacter calcoaceticus</i> GK2
GCF_000962795.1	134533	<i>Acinetobacter parvus</i>
GCA_900096915.1	281376	<i>Acinetobacter seohaensis</i>
GCA_900107285.1	595670	<i>Acinetobacter kyonggiensis</i>
GCF_000368825.1	981336	<i>Acinetobacter ursingii</i> DSM 16037
GCA_000803285.1	1148157	<i>Acinetobacter oleivorans</i>
GCA_900096955.1	1219383	<i>Acinetobacter boissieri</i>
GCA_900096895.1	1226327	<i>Acinetobacter kookii</i>
GCA_000433235.1	1262690	<i>Acinetobacter</i> sp. CAG:196
GCF_000581675.1	1310582	<i>Acinetobacter baumannii</i> 662545-1347
GCA_900095025.1	1673609	<i>Acinetobacter albensis</i>
GCA_001767535.1	1797234	<i>Acinetobacter</i> sp. GWC1_38_13
GCA_001768625.1	1797235	<i>Acinetobacter</i> sp. RIFCSPHIGHO2_12_41_5
GCA_001581975.1	1809055	<i>Acinetobacter</i> sp. DUT-2
GCA_001720685.1	1856846	<i>Acinetobacter</i> sp. 51m

453

454

## 455 **Conclusion**

456 In conclusion, we confirmed the classification of A1S\_0222 as a Type II N6-adenine  
457 DNA methyltransferase recognizing GAATTC in line with the REBASE *in silico*  
458 classification [51]. A1S\_0222 seems to act as an orphan methyltransferase since no  
459 evidence for an associated endonuclease could be found in REBASE. We propose  
460 the name AamA (A*cinetobacter* adenine methyltransferase A) in addition to the  
461 formal names M.AbaBGORF222P and M.Aba17978ORF8565P provided by  
462 REBASE. To the best of our knowledge, this is the first DNA methyltransferase of the  
463 nosocomial pathogen *A. baumannii* that has been experimentally studied.

## 464 **Acknowledgements**

465 This project was funded by the Deutsche Forschungsgemeinschaft (DFG) within  
466 FOR 2251 (project grants EB 285/2-1 and WI 3272/3-1) and in part by additional  
467 contributions from the Bundesministerium für Bildung und Forschung (D.I.S award  
468 Nos. BIOSCAT [05K12YE1]) and the Horizon 2020 programme of the European  
469 Union, iNEXT [653706; D.I.S].

470

471

## 472 **References**

- 473 [1] M. Eveillard, M. Kempf, O. Belmonte, H. Pailhories, M.L. Joly-Guillou,  
474 Reservoirs of *Acinetobacter baumannii* outside the hospital and potential involvement  
475 in emerging human community-acquired infections. *Int J Infect Dis* 17 (2013) e802-  
476 805.
- 477 [2] M.J. McConnell, L. Actis, J. Pachon, *Acinetobacter baumannii*: human  
478 infections, factors contributing to pathogenesis and animal models. *FEMS Microbiol*  
479 *Rev* 37 (2013) 130-155.
- 480 [3] J.H. Baang, P. Axelrod, B.K. Decker, A.M. Hujer, G. Dash, A.R. Truant, R.A.  
481 Bonomo, T. Fekete, Longitudinal epidemiology of multidrug-resistant (MDR)  
482 *Acinetobacter* species in a tertiary care hospital. *Am J Infect Control* 40 (2012) 134-  
483 137.
- 484 [4] E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D.L. Monnet,  
485 C. Pulcini, G. Kahlmeter, J. Kluytmans, Y. Carmeli, M. Ouellette, K. Outtersson, J.

486 Patel, M. Cavaleri, E.M. Cox, C.R. Houchens, M.L. Grayson, P. Hansen, N. Singh, U.  
487 Theuretzbacher, N. Magrini, W.H.O.P.P.L.W. Group, Discovery, research, and  
488 development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria  
489 and tuberculosis. *Lancet Infect Dis* (2017).

490 [5] J. Henrichsen, J. Blom, Correlation between twitching motility and possession  
491 of polar fimbriae in *Acinetobacter calcoaceticus*. *Acta Pathol Microbiol Scand B* 83  
492 (1975) 103-115.

493 [6] J. Henrichsen, The influence of changes in the environment on twitching  
494 motility. *Acta Pathol Microbiol Scand B* 83 (1975) 179-186.

495 [7] C.M. Harding, E.N. Tracy, M.D. Carruthers, P.N. Rather, L.A. Actis, R.S.  
496 Munson, Jr., *Acinetobacter baumannii* strain M2 produces type IV pili which play a  
497 role in natural transformation and twitching motility but not surface-associated  
498 motility. *MBio* 4 (2013).

499 [8] G. Wilharm, J. Piesker, M. Laue, E. Skiebe, DNA uptake by the nosocomial  
500 pathogen *Acinetobacter baumannii* occurs during movement along wet surfaces. *J*  
501 *Bacteriol* 195 (2013) 4146-4153.

502 [9] J.S. Mattick, Type IV pili and twitching motility. *Annu Rev Microbiol* 56 (2002)  
503 289-314.

504 [10] K.M. Clemmer, R.A. Bonomo, P.N. Rather, Genetic analysis of surface motility  
505 in *Acinetobacter baumannii*. *Microbiology* 157 (2011) 2534-2544.

506 [11] E. Skiebe, V. de Berardinis, P. Morczinek, T. Kerrinnes, F. Faber, D. Lepka, B.  
507 Hammer, O. Zimmermann, S. Ziesing, T.A. Wichelhaus, Surface-associated motility,  
508 a common trait of clinical isolates of *Acinetobacter baumannii*, depends on 1, 3-  
509 diaminopropane. *International Journal of Medical Microbiology* 302 (2012) 117-128.

510 [12] A.C. Jacobs, C.E. Blanchard, S.C. Catherman, P.M. Dunman, Y. Murata, An  
511 ribonuclease T2 family protein modulates *Acinetobacter baumannii* abiotic surface  
512 colonization. *PLoS One* 9 (2014) e85729.

513 [13] K.A. Tipton, P.N. Rather, An ompR/envZ Two-Component System Ortholog  
514 Regulates Phase Variation, Osmotic Tolerance, Motility, and Virulence in  
515 *Acinetobacter baumannii* strain AB5075. *J Bacteriol* (2016).

516 [14] J. Collier, Epigenetic regulation of the bacterial cell cycle. *Curr Opin Microbiol*  
517 12 (2009) 722-729.

518 [15] A. Bart, M. Van Passel, K. Van Amsterdam, A. Van Der Ende, Direct detection  
519 of methylation in genomic DNA. *Nucleic acids research* 33 (2005) e124-e124.

520 [16] X. Cheng, Structure and function of DNA methyltransferases. Annual review of  
521 biophysics and biomolecular structure 24 (1995) 293-318.

522 [17] D. Wion, J. Casadesus, N6-methyl-adenine: an epigenetic signal for DNA-  
523 protein interactions. Nat Rev Microbiol 4 (2006) 183-192.

524 [18] S. Adhikari, P.D. Curtis, DNA methyltransferases and epigenetic regulation in  
525 bacteria. FEMS Microbiol Rev 40 (2016) 575-591.

526 [19] T.A. Bickle, D.H. Kruger, Biology of DNA restriction. Microbiol Rev 57 (1993)  
527 434-450.

528 [20] M.G. Marinus, N.R. Morris, Isolation of deoxyribonucleic acid methylase  
529 mutants of *Escherichia coli* K-12. J Bacteriol 114 (1973) 1143-1150.

530 [21] J.E. Brooks, R.M. Blumenthal, T.R. Gingeras, The isolation and  
531 characterization of the *Escherichia coli* DNA adenine methylase (*dam*) gene. Nucleic  
532 Acids Res 11 (1983) 837-851.

533 [22] G. Badie, D.M. Heithoff, R.L. Sinsheimer, M.J. Mahan, Altered levels of  
534 Salmonella DNA adenine methylase are associated with defects in gene expression,  
535 motility, flagellar synthesis, and bile resistance in the pathogenic strain 14028 but not  
536 in the laboratory strain LT2. J Bacteriol 189 (2007) 1556-1564.

537 [23] S. Falker, J. Schilling, M.A. Schmidt, G. Heusipp, Overproduction of DNA  
538 adenine methyltransferase alters motility, invasion, and the lipopolysaccharide O-  
539 antigen composition of *Yersinia enterocolitica*. Infect Immun 75 (2007) 4990-4997.

540 [24] K.H. Choi, A. Kumar, H.P. Schweizer, A 10-min method for preparation of  
541 highly electrocompetent *Pseudomonas aeruginosa* cells: application for DNA  
542 fragment transfer between chromosomes and plasmid transformation. J Microbiol  
543 Methods 64 (2006) 391-397.

544 [25] B.S. Rao, A. Buckler-White, Direct visualization of site-specific and strand-  
545 specific DNA methylation patterns in automated DNA sequencing data. Nucleic Acids  
546 Res 26 (1998) 2505-2507.

547 [26] C.E. Blanchet, A. Spilotros, F. Schwemmer, M.A. Graewert, A. Kikhney, C.M.  
548 Jeffries, D. Franke, D. Mark, R. Zengerle, F. Cipriani, S. Fiedler, M. Roessle, D.I.  
549 Svergun, Versatile sample environments and automation for biological solution X-ray  
550 scattering experiments at the P12 beamline (PETRA III, DESY). J Appl Crystallogr 48  
551 (2015) 431-443.

552 [27] A. Round, F. Felisaz, L. Fodinger, A. Gobbo, J. Huet, C. Villard, C.E. Blanchet,  
553 P. Pernot, S. McSweeney, M. Roessle, D.I. Svergun, F. Cipriani, BioSAXS Sample

554 Changer: a robotic sample changer for rapid and reliable high-throughput X-ray  
555 solution scattering experiments. *Acta Crystallogr D Biol Crystallogr* 71 (2015) 67-75.

556 [28] D. Franke, A.G. Kikhney, D.I. Svergun, Automated acquisition and analysis of  
557 small angle X-ray scattering data. *Nuclear Instruments and Methods in Physics*  
558 *Research Section A: Accelerators, Spectrometers, Detectors and Associated*  
559 *Equipment* 689 (2012) 52-59.

560 [29] D. Franke, C.M. Jeffries, D.I. Svergun, Correlation Map, a goodness-of-fit test  
561 for one-dimensional X-ray scattering spectra. *Nat Methods* 12 (2015) 419-422.

562 [30] D. Franke, M.V. Petoukhov, P.V. Konarev, A. Panjkovich, A. Tuukkanen,  
563 H.D.T. Mertens, A.G. Kikhney, N.R. Hajizadeh, J.M. Franklin, C.M. Jeffries, D.I.  
564 Svergun, ATSAS 2.8: a comprehensive data analysis suite for small-angle scattering  
565 from macromolecular solutions. *J Appl Crystallogr* 50 (2017) 1212-1225.

566 [31] P.V. Konarev, D.I. Svergun, A posteriori determination of the useful data range  
567 for small-angle scattering experiments on dilute monodisperse systems. *IUCrJ* 2  
568 (2015) 352-360.

569 [32] A. Guinier, La diffraction des rayons X aux très petits angles : application à  
570 l'étude de phénomènes ultramicroscopiques. *Ann Phys* 11 (1939) 161-237.

571 [33] D. Svergun, Determination of the regularization parameter in indirect-transform  
572 methods using perceptual criteria. *Journal of Applied Crystallography* 25 (1992) 495-  
573 503.

574 [34] H. Fischer, M. de Oliveira Neto, H.B. Napolitano, I. Polikarpov, A.F. Craievich,  
575 Determination of the molecular weight of proteins in solution from a single small-  
576 angle X-ray scattering measurement on a relative scale. *Journal of Applied*  
577 *Crystallography* 43 (2010) 101-109.

578 [35] R.P. Rambo, J.A. Tainer, Accurate assessment of mass, models and  
579 resolution by small-angle scattering. *Nature* 496 (2013) 477-481.

580 [36] M.V. Petoukhov, D. Franke, A.V. Shkumatov, G. Tria, A.G. Kikhney, M. Gajda,  
581 C. Gorba, H.D. Mertens, P.V. Konarev, D.I. Svergun, New developments in the  
582 ATSAS program package for small-angle scattering data analysis. *J Appl Crystallogr*  
583 45 (2012) 342-350.

584 [37] C.M. Jeffries, M.A. Graewert, C.E. Blanchet, D.B. Langley, A.E. Whitten, D.I.  
585 Svergun, Preparing monodisperse macromolecular samples for successful biological  
586 small-angle X-ray and neutron-scattering experiments. *Nat Protoc* 11 (2016) 2122-  
587 2153.

588 [38] M.V. Petoukhov, D.I. Svergun, Ambiguity assessment of small-angle  
589 scattering curves from monodisperse systems. *Acta Crystallogr D Biol Crystallogr* 71  
590 (2015) 1051-1058.

591 [39] D.I. Svergun, Restoring low resolution structure of biological macromolecules  
592 from solution scattering using simulated annealing. *Biophys J* 76 (1999) 2879-2886.

593 [40] M.B. Kozin, D.I. Svergun, Automated matching of high- and low-resolution  
594 structural models. *Journal of Applied Crystallography* 34 (2001) 33-41.

595 [41] V.V. Volkov, D.I. Svergun, Uniqueness of ab initio shape determination in  
596 small-angle scattering. *Journal of Applied Crystallography* 36 (2003) 860-864.

597 [42] A.T. Tuukkanen, G.J. Kleywegt, D.I. Svergun, Resolution of ab initio shapes  
598 determined from small-angle scattering. *IUCrJ* 3 (2016) 440-447.

599 [43] E. Valentini, A.G. Kikhney, G. Previtali, C.M. Jeffries, D.I. Svergun, SASBDB,  
600 a repository for biological small-angle scattering data. *Nucleic Acids Res* 43 (2015)  
601 D357-363.

602 [44] L.A. Kelley, S. Mezulis, C.M. Yates, M.N. Wass, M.J. Sternberg, The Phyre2  
603 web portal for protein modeling, prediction and analysis. *Nat Protoc* 10 (2015) 845-  
604 858.

605 [45] D. Svergun, C. Barberato, M.H.J. Koch, CRY SOL - a Program to Evaluate X-  
606 ray Solution Scattering of Biological Macromolecules from Atomic Coordinates.  
607 *Journal of Applied Crystallography* 28 (1995) 768-773.

608 [46] A. Panjkovich, D.I. Svergun, Deciphering conformational transitions of proteins  
609 by small angle X-ray scattering and normal mode analysis. *Phys Chem Chem Phys*  
610 18 (2016) 5707-5719.

611 [47] A.C. Roth, G.H. Gonnet, C. Dessimoz, Algorithm of OMA for large-scale  
612 orthology inference. *BMC Bioinformatics* 9 (2008) 518.

613 [48] I. Ebersberger, S. Strauss, A. von Haeseler, HaMStR: profile hidden markov  
614 model based search for orthologs in ESTs. *BMC Evol Biol* 9 (2009) 157.

615 [49] G. Wilharm, E. Skiebe, P.G. Higgins, M.T. Poppel, U. Blaschke, S. Leser, C.  
616 Heider, M. Heindorf, P. Brauner, U. Jackel, K. Bohland, C. Cuny, A. Lopinska, P.  
617 Kaminski, M. Kasprzak, M. Bochenski, O. Ciebiera, M. Tobolka, K.M. Zolnierowicz, J.  
618 Siekiera, H. Seifert, S. Gagne, S.P. Salcedo, M. Kaatz, F. Layer, J.K. Bender, S.  
619 Fuchs, T. Semmler, Y. Pfeifer, L. Jerzak, Relatedness of wildlife and livestock avian  
620 isolates of the nosocomial pathogen *Acinetobacter baumannii* to lineages spread in  
621 hospitals worldwide. *Environ Microbiol* 19 (2017) 4349-4364.

622 [50] R.J. Roberts, T. Vincze, J. Posfai, D. Macelis, REBASE: restriction enzymes  
623 and methyltransferases. *Nucleic Acids Res* 31 (2003) 418-420.

624 [51] R.J. Roberts, T. Vincze, J. Posfai, D. Macelis, REBASE--a database for DNA  
625 restriction and modification: enzymes, genes and genomes. *Nucleic Acids Res* 43  
626 (2015) D298-299.

627 [52] S. Urig, H. Gowher, A. Hermann, C. Beck, M. Fatemi, A. Humeny, A. Jeltsch,  
628 The *Escherichia coli* dam DNA methyltransferase modifies DNA in a highly  
629 processive reaction. *J Mol Biol* 319 (2002) 1085-1096.

630 [53] G. Schluckebier, M. Kozak, N. Bleimling, E. Weinhold, W. Saenger, Differential  
631 binding of S-adenosylmethionine S-adenosylhomocysteine and Sinefungin to the  
632 adenine-specific DNA methyltransferase M.TaqI. *J Mol Biol* 265 (1997) 56-67.

633

634

635

636

637

638

639

640

641

642

643

644


645

646

647

648

649 **Supplementary material**




650  
 651 **Fig. S1: Sanger DNA sequencing indicates A1S\_0222-dependent methylation of**  
 652 **adenine within a GAATTC recognition site.** In this automated dye terminator  
 653 sequencing an m6A methylation in template DNA is indicated by an increased  
 654 complementary T signal in the DNA sequence [25]. After an m6A methylation the T-  
 655 peak pattern changes to an increase of the first T-peak and a lower second T-peak  
 656 right after the methylated adenine. Details of sequencing chromatograms with the  
 657 putative recognition site GAATTC boxed. In non-treated DNA the first T-peaks are  
 658 lower compared to the second T-peaks on forward and reverse strand (yellow box).  
 659 Upon treatment of Int1 DNA with purified A1S\_0222 the first T-peak intensifies on  
 660 both strands whereas the second T-peak attenuates. This suggests the recognition  
 661 site of A1S\_0222 to be GAATTC and the second adenine (underlined) to be  
 662 methylated.

663

664

665



666

667 **Fig. S2: Kinetic analysis of the A1S\_0222 methylation reaction (A) and**  
 668 **comparison to activity of EcoRI methyltransferase (from *E. coli* RY13) (B).** For  
 669 the methylation assay 1 µg of DNA (Seq3) was used. Untreated Seq3 is indicated by  
 670 “-/-“. DNA (Seq3) not treated with A1S\_0222 (7.38 µg) or EcoRI methyltransferase  
 671 (40U), but treated with EcoRI endonuclease is shown by “-/+“. Seq3 incubated with  
 672 A1S\_0222 or EcoRI methyltransferase, but without EcoRI endonuclease treatment is  
 673 indicated by “+/-“. Seq3 treated with A1S\_0222 or EcoRI methyltransferase and  
 674 subsequently treated with EcoRI endonuclease is shown by “+/+”. **A.** 10 minutes after  
 675 incubation with A1S\_0222 about 30% of DNA is protected from restriction. After 40  
 676 minutes of incubation about 80% of DNA is methylated by A1S\_0222. **B.** After 30  
 677 seconds of incubation with EcoRI methyltransferase, 1 µg of DNA is completely  
 678 protected from restriction by EcoRI endonuclease.

679